Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Anticuerpos monoclonales anti-BAMBI inhibidores para el tratamiento de enfermedades inflamatorias

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20161021002
Publicado:
01/12/2016
Caducidad:
01/12/2017
Resumen:
Un centro de investigación español ha desarrollado anticuerpos monoclonales anti-BAMBI inhibidores (mAbs) eficientes en el tratamiento de la artritis inflamatoria, psoriasis y colitis. La inhibición gradual de BAMBI utilizando mAbs causa un incremento dependiente de la dosis en el número de células TREG y una reducción del número de células TH17 in vitro. El tratamiento de ratones normales con mAbs anti-BAMBI inhibe el desarrollo de la artritis autoinmune inducida por colágeno tipo II, psoriasis inducida por manano derivada de Saccharomyces cerevisiae y colitis inducida por dextrano sulfato de sodio. El centro de investigación busca una compañía biotecnológica o farmacéutica que desarrolle productos biológicos con el fin de establecer acuerdos de investigación y licencia.


Details

Tittle:
Anti-BAMBI monoclonal antibodies for the treatment of inflammatory diseases
Summary:
A joint Spanish research centre has developed inhibitory anti-BAMBI monoclonal antibodies (mAbs) that are efficient for the treatment of inflammatory arthritis, psoriasis and colitis. It is looking for a biotech or pharma company developing biologicals, for research cooperation and licensing agreements.
Description:
Transforming growth factor -Y-beta; (TGF-Y-beta;) exerts a prominent role in the establishment of immunological tolerance. In this regard, TGF-Y-beta; drives the conversion of CD4+ lymphocytes into either tolerogenic regulatory T (TREG) cells or pro-inflammatory TH17 cells. Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) is a transmembrane protein that antagonizes TGF-Y-beta; family signals by preventing the formation of active receptor complexes. BAMBI expression is induced in CD4+ cells once they are activated and TGF-Y-beta; further enhances its expression. In addition, BAMBI regulates the strength of TGF-Y-beta; signalling and the expression of CD25 and IL-2 signalling in CD4+ cells. Accordingly, its deficiency in knockout mice increases the capacity of CD4+ cells to differentiate into TREG cells and decreases their capacity to differentiate into TH17 cells in vitro and in vivo.
Advantages and Innovations:
· The anti-BAMBI mAbs herein presented recognize both mouse and human BAMBI and inhibit its activity.
· Gradual inhibition of BAMBI using mAbs causes a dose-dependent increase in the number of TREG cells and a decrease in the number of TH17 cells in vitro.
· Treatment of normal mice with anti-BAMBI mAbs inhibits the development of collagen type II-induced autoimmune arthritis, Saccharomyces cerevisiae-derived mannan-induced psoriasis and psoriatic arthritis and dextran sulfate sodium-induced colitis.
Stage of Development:
Concept stage
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Biotech, Pharma company working with monoclonal antibodies for treatment.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos